<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioPharma</title>
	<atom:link href="https://www.worldpharmatoday.com/biopharma/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Fri, 24 Apr 2026 11:06:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>BioPharma</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Gene Expression Systems Explained for Biotech Founders</title>
		<link>https://www.worldpharmatoday.com/production-manufacturing/gene-expression-systems-explained-for-biotech-founders/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 24 Apr 2026 11:06:47 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Knowledge Bank]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/gene-expression-systems-explained-for-biotech-founders/</guid>

					<description><![CDATA[<p>Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.</p>
The post <a href="https://www.worldpharmatoday.com/production-manufacturing/gene-expression-systems-explained-for-biotech-founders/">Gene Expression Systems Explained for Biotech Founders</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>The Hidden Cost of Licensing in Biologic Drug Development</title>
		<link>https://www.worldpharmatoday.com/drug-research/the-hidden-cost-of-licensing-in-biologic-drug-development/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 24 Apr 2026 10:47:39 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/the-hidden-cost-of-licensing-in-biologic-drug-development-and-why-more-biotech-startups-are-rethinking-it/</guid>

					<description><![CDATA[<p>Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/the-hidden-cost-of-licensing-in-biologic-drug-development/">The Hidden Cost of Licensing in Biologic Drug Development</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Trump Order Targets Faster Psychedelic Drug Reviews by FDA</title>
		<link>https://www.worldpharmatoday.com/news/trump-order-targets-faster-psychedelic-drug-reviews-by-fda/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 23 Apr 2026 07:08:09 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/trump-order-targets-faster-psychedelic-drug-reviews-by-fda/</guid>

					<description><![CDATA[<p>The Trump administration has introduced a new executive order designed to accelerate Psychedelic Drug Reviews, marking a notable policy move aimed at expediting regulatory pathways for emerging mental health treatments. The directive focuses on advancing FDA evaluation processes for investigational psychedelic therapies, particularly those addressing conditions such as post-traumatic stress disorder (PTSD), anxiety, and depression. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/trump-order-targets-faster-psychedelic-drug-reviews-by-fda/">Trump Order Targets Faster Psychedelic Drug Reviews by FDA</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology</title>
		<link>https://www.worldpharmatoday.com/news/deepcyte-raises-1-5m-funding-to-advance-ai-drug-toxicology/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 10 Apr 2026 11:03:40 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/deepcyte-raises-1-5m-funding-to-advance-ai-drug-toxicology/</guid>

					<description><![CDATA[<p>DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human cells at single-cell resolution, addressing long-standing gaps in preclinical testing. Drug toxicity remains one of the [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/deepcyte-raises-1-5m-funding-to-advance-ai-drug-toxicology/">DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Clinical Trial Patient Recruitment and Site Selection</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/clinical-trial-patient-recruitment-and-site-selection/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 30 Mar 2026 11:55:52 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[IT & Data Management]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/clinical-trial-patient-recruitment-and-site-selection/</guid>

					<description><![CDATA[<p>Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/clinical-trial-patient-recruitment-and-site-selection/">Clinical Trial Patient Recruitment and Site Selection</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Global Clinical Trials with Local Expertise in 2026</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/global-clinical-trials-with-local-expertise-in-2026/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 30 Mar 2026 11:45:53 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/global-clinical-trials-with-local-expertise-in-2026/</guid>

					<description><![CDATA[<p>Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/global-clinical-trials-with-local-expertise-in-2026/">Global Clinical Trials with Local Expertise in 2026</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Adaptive CRO Models in Clinical Development Strategy</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/adaptive-cro-models-in-clinical-development-strategy/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 30 Mar 2026 11:44:19 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/adaptive-cro-models-in-clinical-development-strategy/</guid>

					<description><![CDATA[<p>Explore the evolution of flexible clinical research organization frameworks that use real-time data to adjust trial parameters, reduce uncertainty, and optimize outcomes for global biotech innovation in 2026.</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/adaptive-cro-models-in-clinical-development-strategy/">Adaptive CRO Models in Clinical Development Strategy</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Integrated Drug Development Consulting for Pharmaceuticals</title>
		<link>https://www.worldpharmatoday.com/drug-research/integrated-drug-development-consulting-for-pharmaceuticals/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 30 Mar 2026 11:41:34 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/integrated-drug-development-consulting-for-pharmaceuticals/</guid>

					<description><![CDATA[<p>Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/integrated-drug-development-consulting-for-pharmaceuticals/">Integrated Drug Development Consulting for Pharmaceuticals</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Strategic CRO Partnerships in Modern Drug Development</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/strategic-cro-partnerships-in-modern-drug-development/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 30 Mar 2026 11:27:26 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/strategic-cro-partnerships-in-modern-drug-development/</guid>

					<description><![CDATA[<p>Examining the shift from transactional outsourcing to collaborative alliances, where shared risk and integrated data drive clinical success in the 2026 pharmaceutical landscape.</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/strategic-cro-partnerships-in-modern-drug-development/">Strategic CRO Partnerships in Modern Drug Development</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Axplora $60M Investment Expands HPAPI Manufacturing Capacity</title>
		<link>https://www.worldpharmatoday.com/news/axplora-60m-investment-expands-hpapi-manufacturing-capacity/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 26 Mar 2026 10:38:37 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/axplora-60m-investment-expands-hpapi-manufacturing-capacity/</guid>

					<description><![CDATA[<p>Axplora has reached a key milestone in its ongoing investment strategy, advancing a $60 million programme dedicated to strengthening HPAPI manufacturing capabilities at its Farmabios site in Gropello Cairoli. The latest development involves the construction of a new 4,500 m², three-storey R&#38;D and laboratory hub. This facility is designed to accelerate development timelines, expand execution [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/axplora-60m-investment-expands-hpapi-manufacturing-capacity/">Axplora $60M Investment Expands HPAPI Manufacturing Capacity</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
